DeZwarteRidder schreef op 19 mei 2019 om 21:31:
Je vraagt erom en dus krijg je je zin:
Allemaal mislukte onzin:
Probiodrug´s meeting of the Scientific Advisory Board highlighted programs in metabolic and neuronal disorders.
Halle (Saale), Germany //
Probiodrug AG conducted its 11th SAB meeting on December 12th and 13th to review in depth the company’s programs and focus.
Prof. A. Kleemann, chairing the meeting, concluded, that in the view of the board, the company has appropriately prioritized its drug development programs and made outstanding achievements in its pharmaceutical research. The board includes as additional members Profs M. Cawthorne, University of Buckingham, C.H.S. McIntosh, R.A. Pederson, both University of British Columbia, and D. Schomburg from the University of Cologne.
Members of Probiodrug’s Medicinal Chemistry, Enzymology, Molecular Biology and Drug Development departments presented data for projects centering around Type 2 Diabetes, Obesity, Neuronal Disorders, Inflammation and Cancer. The company has strengthened its R&D programs and is focusing on new targets. Among them the work on the GIP-receptor complements Probiodrug’s DPIV-inhibitor program in metabolic disorders. Glutaminyl cyclase is included in the new targets for the treatment of neuronal disorders. Both of these programs are supported by the company’s IP portfolio. Highlights of the meeting included presentation of exciting preclinical and phase II clinical data of Probiodrug’s drug candidate, P93/01. The company expects to formally present the Phase II clinical trial results at the 2004 diabetes conferences. Guest speakers were Drs. S.A. Hinke, University of Brussels, A. Pospisilik, University of Vienna and S. Rossner, University of Leipzig.
In 2003, Probiodrug’s patenting and publication activities included 78 new patent applications, 15 granted patents, 25 self-driven and collaborative publications, as well as 15 posters and 12 lectures at international meetings.
Probiodrug AG is a biopharmaceutical company that is focused on the discovery, development, and commercialization of therapeutic medicines for the treatment of diabetes, obesity and other serious medical conditions based on its detailed understanding of enzyme and receptor mechanisms.
Hans-Ulrich Demuth, Ph.D.
Chief Executive Officer
D-06120 Halle (Saale)